查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856987

全球基因静默市场：预测至2032年－依产品/服务、机制、技术、应用、最终使用者及地区进行分析

Gene Silencing Market Forecasts to 2032 - Global Analysis By Product & Service, Mechanism, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2025 年，全球基因静默市场规模将达到 114.8 亿美元，到 2032 年将达到 320.7 亿美元，预测期内复合年增长率为 15.8%。

基因静默是一种天然的生物学过程，它透过阻止特定基因产生蛋白质或其他基因产物来控制基因表现。基因静默发生在转录或转录后水平，有效地「关闭」基因，而无需改变其DNA序列。 RNARNA干扰（RNAi）、DNA甲基化和组蛋白修饰等机制在这过程中扮演重要角色。基因静默有助于调节细胞功能、维持基因组稳定性以及抵抗病毒和转座因子。它也被广泛应用于生物技术和医学领域，用于研究基因功能和开发遗传性感染疾病的治疗方法。

遗传性疾病和慢性病发生率上升

RNA干扰（RNAi）、反义寡核苷酸（ASO）和基于CRISPR的定序平台能够对致病基因进行标靶控制。製药公司和生技新兴企业正在拓展其定序研发管线，以应对亨廷顿氏舞蹈症、肌萎缩侧索硬化症（ALS）和遗传性癌症等疾病。与基因组分析和递送系统的整合能够提高治疗的精准性和组织标靶性。个人化医疗和孤儿药计画正在推动对非侵入性、持久性干预措施的需求。这些因素正在推动基因静默系统的平台创新和临床应用。

安全性和免疫抗原性问题

脱靶效应、免疫活化和毒性等风险会影响平台可靠性和患者疗效。病毒载体和脂质奈米颗粒等递送载体必须在疗效、生物相容性和清除率之间取得平衡。监管机构要求对基因沉默候选药物进行广泛的临床前检验和长期安全性数据核准定序。临床试验的延误和不利事件的报告持续阻碍投资者信心和研发管线的推进。这些限制因素阻碍了基因沉默技术在高风险和免疫敏感治疗领域的应用。

临床验证和核准成功

FDA和EMA对基于RNAi的药物（例如patisiran和givosiran）的核准，检验了其治疗效果和商业性可行性。临床试验表明，这些药物能够持续抑制基因表达，减轻症状，并改善罕见疾病和慢性病的生物标记。学术界和产业界的赞助商正在加速推进RNAi在癌症、代谢性疾病和感染疾病领域的适应症拓展。製药业的合作与授权协议正在推动对可扩展、受监管的基因定序平台的需求。这些趋势正在促进临床转化和治疗方法多样化的发展。

智慧财产权与市场竞争

专利纠纷、许可限制和自由运营方面的挑战限制了创新和市场准入。早期参与企业和专有递送系统的主导地位限制了新兴企业和学术衍生企业的进入。智慧财产权格局的分散化使跨国商业化和策略联盟变得复杂。来自 CRISPR、碱基编辑和表观遗传调控平台的竞争压力降低了投资者对传统定序方法的关注。这些风险持续限制该平台的扩充性及其在治疗市场的长期地位。

新冠疫情的影响：

疫情扰乱了基因静默计画的临床试验、生产和监管进程。封锁和资源重新分配延缓了罕见疾病和肿瘤临床试验的患者招募和数据收集。然而，由于mRNA疫苗的成功以及大众对基因医学的认知度提高，人们对基于RNA的平台产生了浓厚的兴趣。对递送系统、免疫抗原性缓解和远端监测的投资加速了平台创新。疫情后的策略已将基因静默作为精准医疗和治疗韧性的核心支柱。这种转变加强了对定序技术的长期投资和监管参与。

预计在预测期内， RNA干扰（RNAi）领域将是最大的细分市场。

由于其高效的机制、成熟的临床应用以及在多种疾病领域的广泛适用性，RNA干扰（RNAi）领域预计将在预测期内占据最大的市场份额。 RNAi平台利用siRNA和shRNA构建体以高特异性和持久性沉默标靶基因。脂质奈米颗粒递送以及与组织特异性启动子的整合可提高治疗的精确度和安全性。核准的RNAi药物和处于后期研发阶段的候选药物已在肝病学、神经病学和眼科学等领域展现出疗效。製药研发和学术研究对可扩展和模组化RNAi平台的需求日益增长。

预计在预测期内，软体和生物资讯学工具领域将实现最高的复合年增长率。

软体与生物资讯学工具领域预计将在预测期内呈现最高成长率，因为数据复杂性和标靶验证推动了对高阶分析的需求。平台支援RNAi、ASO和CRISPR工作流程中的序列设计、脱靶预测和递送优化。人工智慧和机器学习演算法能够实现生物标记发现、毒性建模以及跨临床队列的患者分层。云端基础的基础设施和模组化流程提高了研究和商业环境中的可扩展性和可访问性。对互通性、安全且经过临床检验的生物资讯工具的需求正在不断增长，以满足定序技术开发和监管申报的需求。

比最大的地区

在预测期内，北美预计将占据最大的市场份额，这主要得益于其先进的生物技术生态系统、清晰的监管环境和完善的临床基础设施。美国和加拿大的公司正在罕见疾病、肿瘤和神经病学计画中部署基因静默平台，并整合了交付和分析功能。对基因组医学的投资、产学合作以及美国食品药物管理局（FDA）的参与，都为平台的扩充性和检验提供了支持。领先的治疗药物开发商、合约研究组织（CRO）和研究机构的存在，正在推动创新和标准化。这些因素共同促成了北美在基因静默的商业化和临床应用领域的领先地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于医疗现代化、遗传疾病负担以及生物技术投资在该地区各国经济中的融合发展。中国、印度、日本和韩国等国家正在公共卫生计画、学术研究和临床试验中推广基因静默平台。政府支持的倡议正在推动RNA和寡核苷酸疗法的基础建设、新兴企业孵化以及国际研究合作。本地企业正在提供经济高效且符合当地实际情况的解决方案，以满足疾病特征和合规性需求。这些趋势正在推动该地区基因静默创新和疗法应用的成长。

免费客製化服务

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 原始研究资料
    • 二手研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 市场机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 公司间的竞争

5. 全球基因静默市场（依产品和服务划分）

  • 试剂和试剂盒
  • 装置
  • 寡核苷酸和RNA分子
  • 软体、生物资讯学工具
  • 基因静默服务
  • 其他产品和服务

6. 全球基因静默市场依机制划分

  • 转录基因静默
  • 转录后基因静默
  • 表观遗传调控

7. 全球基因静默市场（依技术划分）

  • RNA干扰（RNAi）
  • 反义寡核苷酸（ASO）
  • CRISPR干扰（CRISPRi）
  • 表观遗传定序
  • siRNA/shRNA递送系统

8. 全球基因静默市场（依应用领域划分）

  • 药物发现与开发
  • 治疗药物生产
  • 功能基因体学
  • 目标检验
  • 疾病模型
  • 其他用途

9. 全球基因静默市场（依最终用户划分）

  • 製药和生物技术公司
  • 学术研究机构
  • CRO/CDMO
  • 医院和诊断实验室
  • 其他最终用户

第十章 全球基因静默市场（依地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章：公司简介

  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Dicerna Pharmaceuticals
  • Sirnaomics
  • Arbutus Biopharma
  • Olix Pharmaceuticals
  • Benitec Biopharma
  • Sylentis
  • Genevant Sciences
  • RXi Pharmaceuticals
  • Intellia Therapeutics
  • Editas Medicine
  • Beam Therapeutics
Product Code: SMRC31852

According to Stratistics MRC, the Global Gene Silencing Market is accounted for $11.48 billion in 2025 and is expected to reach $32.07 billion by 2032 growing at a CAGR of 15.8% during the forecast period. Gene silencing is a natural biological process that regulates gene expression by preventing specific genes from producing proteins or other gene products. It can occur at the transcriptional or post-transcriptional level, effectively "turning off" a gene without altering its DNA sequence. Mechanisms such as RNA interference (RNAi), DNA methylation, and histone modification play key roles in this process. Gene silencing helps control cellular functions, maintain genome stability, and defend against viruses or transposable elements. It is also widely used in biotechnology and medicine for studying gene function and developing treatments for genetic and infectious diseases.

Market Dynamics:

Driver:

Rising prevalence of genetic & chronic diseases

RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR-based silencing platforms enable targeted modulation of disease-causing genes. Pharmaceutical firms and biotech startups are scaling silencing pipelines to address conditions such as Huntington's, ALS, and hereditary cancers. Integration with genomic profiling and delivery systems enhances therapeutic precision and tissue targeting. Demand for non-invasive and durable interventions is rising across personalized medicine and orphan drug programs. These dynamics are propelling platform innovation and clinical adoption across gene silencing ecosystems.

Restraint:

Safety and immunogenicity concerns

Off-target effects, immune activation, and toxicity risks degrade platform reliability and patient outcomes. Delivery vehicles such as viral vectors and lipid nanoparticles must balance efficacy with biocompatibility and clearance. Regulatory bodies require extensive preclinical validation and long-term safety data to approve silencing candidates. Clinical trial delays and adverse event reporting continue to hinder investor confidence and pipeline progression. These constraints are hampering adoption across high-risk and immunologically sensitive therapeutic areas.

Opportunity:

Successful clinical proof-of-concept and approvals

FDA and EMA approvals of RNAi-based drugs such as patisiran and givosiran validate therapeutic efficacy and commercial viability. Clinical trials demonstrate durable gene knockdown, symptom reduction, and biomarker improvement across rare and chronic conditions. Expansion into oncology, metabolic, and infectious disease indications is accelerating across academic and industry sponsors. Demand for scalable and regulatory-aligned silencing platforms is rising across pharma partnerships and licensing deals. These trends are fostering growth across clinical translation and therapeutic diversification.

Threat:

Intellectual property & market competition

Patent disputes, licensing restrictions, and freedom-to-operate challenges constrain innovation and market entry. Dominance of early movers and proprietary delivery systems limits access for emerging players and academic spinouts. Fragmented IP landscapes complicate cross-border commercialization and strategic alliances. Competitive pressure from CRISPR, base editing, and epigenetic modulation platforms reduces investor focus on traditional silencing modalities. These risks continue to limit platform scalability and long-term positioning across therapeutic markets.

Covid-19 Impact:

The pandemic disrupted clinical trials, manufacturing, and regulatory timelines across gene silencing programs. Lockdowns and resource reallocation delayed patient recruitment and data collection across rare disease and oncology trials. However, interest in RNA-based platforms surged due to mRNA vaccine success and public awareness of genetic medicine. Investment in delivery systems, immunogenicity mitigation, and remote monitoring accelerated platform innovation. Post-pandemic strategies now include gene silencing as a core pillar of precision medicine and therapeutic resilience. These shifts are reinforcing long-term investment and regulatory engagement across silencing technologies.

The RNA interference (RNAi) segment is expected to be the largest during the forecast period

The RNA interference (RNAi) segment is expected to account for the largest market share during the forecast period due to its validated mechanism, clinical maturity, and broad applicability across disease areas. RNAi platforms use siRNA and shRNA constructs to silence target genes with high specificity and durability. Integration with lipid nanoparticle delivery and tissue-specific promoters enhances therapeutic precision and safety. Approved RNAi drugs and late-stage candidates demonstrate efficacy across liver, nerve, and ocular indications. Demand for scalable and modular RNAi platforms is rising across pharma pipelines and academic research.

The software & bioinformatics tools segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the software & bioinformatics tools segment is predicted to witness the highest growth rate as data complexity and target validation drive demand for advanced analytics. Platforms support sequence design, off-target prediction, and delivery optimization across RNAi, ASO, and CRISPR workflows. AI and machine learning algorithms enable biomarker discovery, toxicity modelling, and patient stratification across clinical cohorts. Cloud-based infrastructure and modular pipelines improve scalability and accessibility across research and commercial environments. Demand for interoperable, secure, and clinically validated bioinformatics tools is rising across silencing development and regulatory submission.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced biotech ecosystem, regulatory clarity, and clinical infrastructure. U.S. and Canadian firms deploy gene silencing platforms across rare disease, oncology, and neurology programs with integrated delivery and analytics. Investment in genomic medicine, academic-industry partnerships, and FDA engagement supports platform scalability and validation. Presence of leading therapeutic developers, CROs, and research institutions drives innovation and standardization. These factors are propelling North America's leadership in gene silencing commercialization and clinical translation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, genetic disease burden, and biotech investment converge across regional economies. Countries like China, India, Japan, and South Korea scale gene silencing platforms across public health programs, academic research, and clinical trials. Government-backed initiatives support infrastructure development, startup incubation, and international collaboration across RNA and oligonucleotide therapeutics. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. These trends are accelerating regional growth across gene silencing innovation and therapeutic deployment.

Key players in the market

Some of the key players in Gene Silencing Market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Sirnaomics, Arbutus Biopharma, Olix Pharmaceuticals, Benitec Biopharma, Sylentis, Genevant Sciences, RXi Pharmaceuticals, Intellia Therapeutics, Editas Medicine and Beam Therapeutics.

Key Developments:

In September 2025, Ionis secured FDA approvals for TRYNGOLZA (for familial chylomicronemia syndrome, FCS) and DAWNZERA (for hereditary angioedema, HAE), marking a pivotal commercial milestone. Clinical trials showed 72% triglyceride reduction and 85% fewer pancreatitis events for olezarsen, the active compound in TRYNGOLZA. These approvals validate Ionis' RNA-targeted platform and expand its rare disease portfolio.

In February 2025, Alnylam unveiled its TRITON Phase 3 program for nucresiran, a next-generation TTR silencer targeting ATTR-CM and hATTR-PN. The candidate builds on Alnylam's RNAi leadership in amyloidosis and aims to deliver durable knockdown with improved delivery. It complements the company's existing portfolio and supports long-term franchise sustainability in rare diseases.

Product & Services Covered:

  • Reagents & Kits
  • Instruments
  • Oligonucleotides & RNA Molecules
  • Software & Bioinformatics Tools
  • Gene Silencing Services
  • Other Product & Services

Mechanisms Covered:

  • Transcriptional Gene Silencing
  • Post-Transcriptional Gene Silencing
  • Epigenetic Modulation

Technologies Covered:

  • RNA Interference (RNAi)
  • Antisense Oligonucleotides (ASOs)
  • CRISPR Interference (CRISPRi)
  • Epigenetic Silencing
  • siRNA/shRNA Delivery Systems

Applications Covered:

  • Drug Discovery & Development
  • Therapeutics Manufacturing
  • Functional Genomics
  • Target Validation
  • Disease Modeling
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • CROs & CDMOs
  • Hospitals & Diagnostic Labs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Gene Silencing Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Reagents & Kits
  • 5.3 Instruments
  • 5.4 Oligonucleotides & RNA Molecules
  • 5.5 Software & Bioinformatics Tools
  • 5.6 Gene Silencing Services
  • 5.7 Other Product & Services

6 Global Gene Silencing Market, By Mechanism

  • 6.1 Introduction
  • 6.2 Transcriptional Gene Silencing
  • 6.3 Post-Transcriptional Gene Silencing
  • 6.4 Epigenetic Modulation

7 Global Gene Silencing Market, By Technology

  • 7.1 Introduction
  • 7.2 RNA Interference (RNAi)
  • 7.3 Antisense Oligonucleotides (ASOs)
  • 7.4 CRISPR Interference (CRISPRi)
  • 7.5 Epigenetic Silencing
  • 7.6 siRNA/shRNA Delivery Systems

8 Global Gene Silencing Market, By Application

  • 8.1 Introduction
  • 8.2 Drug Discovery & Development
  • 8.3 Therapeutics Manufacturing
  • 8.4 Functional Genomics
  • 8.5 Target Validation
  • 8.6 Disease Modeling
  • 8.7 Other Applications

9 Global Gene Silencing Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Academic & Research Institutions
  • 9.4 CROs & CDMOs
  • 9.5 Hospitals & Diagnostic Labs
  • 9.6 Other End Users

10 Global Gene Silencing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Alnylam Pharmaceuticals
  • 12.2 Ionis Pharmaceuticals
  • 12.3 Arrowhead Pharmaceuticals
  • 12.4 Silence Therapeutics
  • 12.5 Dicerna Pharmaceuticals
  • 12.6 Sirnaomics
  • 12.7 Arbutus Biopharma
  • 12.8 Olix Pharmaceuticals
  • 12.9 Benitec Biopharma
  • 12.10 Sylentis
  • 12.11 Genevant Sciences
  • 12.12 RXi Pharmaceuticals
  • 12.13 Intellia Therapeutics
  • 12.14 Editas Medicine
  • 12.15 Beam Therapeutics

List of Tables

  • Table 1 Global Gene Silencing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Gene Silencing Market Outlook, By Product & Service (2024-2032) ($MN)
  • Table 3 Global Gene Silencing Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 4 Global Gene Silencing Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 5 Global Gene Silencing Market Outlook, By Oligonucleotides & RNA Molecules (2024-2032) ($MN)
  • Table 6 Global Gene Silencing Market Outlook, By Software & Bioinformatics Tools (2024-2032) ($MN)
  • Table 7 Global Gene Silencing Market Outlook, By Gene Silencing Services (2024-2032) ($MN)
  • Table 8 Global Gene Silencing Market Outlook, By Other Product & Services (2024-2032) ($MN)
  • Table 9 Global Gene Silencing Market Outlook, By Mechanism (2024-2032) ($MN)
  • Table 10 Global Gene Silencing Market Outlook, By Transcriptional Gene Silencing (2024-2032) ($MN)
  • Table 11 Global Gene Silencing Market Outlook, By Post-Transcriptional Gene Silencing (2024-2032) ($MN)
  • Table 12 Global Gene Silencing Market Outlook, By Epigenetic Modulation (2024-2032) ($MN)
  • Table 13 Global Gene Silencing Market Outlook, By Technology (2024-2032) ($MN)
  • Table 14 Global Gene Silencing Market Outlook, By RNA Interference (RNAi) (2024-2032) ($MN)
  • Table 15 Global Gene Silencing Market Outlook, By Antisense Oligonucleotides (ASOs) (2024-2032) ($MN)
  • Table 16 Global Gene Silencing Market Outlook, By CRISPR Interference (CRISPRi) (2024-2032) ($MN)
  • Table 17 Global Gene Silencing Market Outlook, By Epigenetic Silencing (2024-2032) ($MN)
  • Table 18 Global Gene Silencing Market Outlook, By siRNA/shRNA Delivery Systems (2024-2032) ($MN)
  • Table 19 Global Gene Silencing Market Outlook, By Application (2024-2032) ($MN)
  • Table 20 Global Gene Silencing Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 21 Global Gene Silencing Market Outlook, By Therapeutics Manufacturing (2024-2032) ($MN)
  • Table 22 Global Gene Silencing Market Outlook, By Functional Genomics (2024-2032) ($MN)
  • Table 23 Global Gene Silencing Market Outlook, By Target Validation (2024-2032) ($MN)
  • Table 24 Global Gene Silencing Market Outlook, By Disease Modeling (2024-2032) ($MN)
  • Table 25 Global Gene Silencing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global Gene Silencing Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Gene Silencing Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 28 Global Gene Silencing Market Outlook, By Academic & Research Institutions (2024-2032) ($MN)
  • Table 29 Global Gene Silencing Market Outlook, By CROs & CDMOs (2024-2032) ($MN)
  • Table 30 Global Gene Silencing Market Outlook, By Hospitals & Diagnostic Labs (2024-2032) ($MN)
  • Table 31 Global Gene Silencing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.